Clinical Efficacy of Penpulimab Combined Chemotherapy in Non-Squamous NSCLC

Corresponding author: HU Wei,, 13938592975@139.cpm

DOI: 10.12201/bmr.202508.00045

•  

  Abstract: Objective To evaluate the clinical efficacy of Penpulimab, a novel domestic PD-1 inhibitor, combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC). Methods Patients diagnosed with metastatic or locally advanced non-squamous NSCLC in our hospital from October 2021 to December 2022 were retrospectively selected and divided into a control group (receiving standard platinum-containing dual drug chemotherapy) and an observation group (receiving piamprimab combined chemotherapy). The objective response rate (Objective response rate,ORR), progression-free survival (PFS), tumor markers (CYFRA21-1 and CEA), immune function indicators (CD3+, CD4+, CD8+ cell positivity, and CD4+/CD8+ ratio), and adverse events were compared between the two groups. Results After six cycles of treatment, the ORR in the observation group was significantly higher than that in the control group (55.6% vs. 34.4%, P=0.029), and the PFS was also significantly longer (17.0 months vs. 11.0 months, P<0.05). Post-treatment, CYFRA21-1 and CEA levels were significantly lower in the observation group compared to the control group (P<0.05). Additionally, immune function analysis showed that CD3+ and CD4+ cell positivity and the CD4+/CD8+ ratio significantly increased, while CD8+ cell positivity decreased, with a greater improvement observed in the observation group (P<0.05). Both groups experienced varying degrees of adverse effects; however, symptoms were effectively managed. No statistically significant differences were found between the two groups regarding nausea, vomiting, anemia, hepatotoxicity, nephrotoxicity, or rash (P>0.05), but the incidence of neutropenia was higher in the observation group (P<0.05). Conclusion The combination of Penpulimab with platinum-based chemotherapy significantly improves treatment efficacy, reduces tumor marker levels, enhances immune function, and prolongs progression-free survival in patients with advanced non-squamous NSCLC.

  Key words: Non-squamous NSCLC; Penpulimab; Chemotherapy; Immunotherapy; Survival

  Submit time: 22 August 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• 李娜, Luo bingqing. Clinical observation of microwave ablation combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer.. 2025. doi: 10.12201/bmr.202504.00054

  CHENG Ke, XU Shucai. Progress in the treatment of blood hypercoagulability in patients with non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00015

  Zhang Xinzhong. Research progress on folate receptor positive circulating tumor cells and the occurrence and development of non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00024

  付思思. Construction and validation of Nomogram analysis model for nausea and vomiting after lobectomy in non-small cell lung cancer patients. 2025. doi: 10.12201/bmr.202507.00001

  Clinical research progress of PD-1/PD-L1 inhibitor induction therapy in unresectable stage III non-small-cell lung cancer. 2025. doi: 10.12201/bmr.202501.00025

  Liu Yanan, Zhan Ming, Han Fei. Research Progress and Prospects of Finerenone in the Treatment of Diabetic Nephropathy. 2024. doi: 10.12201/bmr.202410.00033

  Jing ZHAO, Junxia HUANG, Xiuhua TANG, Hong WANG. The role of HOXA11-AS/miR-149-3p pathway in the malignant phenotype of lung squamous cell carcinoma. 2022. doi: 10.12201/bmr.202204.00005

  quyanli. Efficacy and safety of preoperative chemotherapy in real world patients with locally advanced gastric/gastroesophageal junction adenocarcinoma. 2024. doi: 10.12201/bmr.202409.00052

  Houyu, Liyong, Zhouweixing, Liyaozaho, Lili. Progress in the study of cryoablation-induced immune effects and combined immunotherapy. 2025. doi: 10.12201/bmr.202503.00061

  Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor combined with bifidobacterium in treatment of oral mucositis after chemotherapy
  Lan? Qinghua 1, Zeng Qingfang 1, Xiao Wei 2, Zhan Tao 1,Zhong Jianming 1, Qiu Liujin 1. 2025. doi: 10.12201/bmr.202505.00045

• ID	Submit time	Number	Download
  1	2025-04-14	bmr.202508.00045V1	Download

• Public  Anonymous  To author only Submit Comments